Pipeline

OVERVIEW

Our current pipeline consists of new molecular entities with relevant mechanism of actions in skin diseases, targeting significant market opportunities in the global dermatology market.

PIPELINE

PRODUCT
CANDIDATE
MOA &
INDICATION
PRE-
CLINICAL
PHASE
1
PHASE
2a
PHASE
2b
PHASE
3
KEY MILESTONES
Sofpironium
Bromide
Topical soft anticholinergic for axillary hyprhidrosis
  • Pivotal P3 initiation in Q1 2019 (US)
  • Pivotal P3 data in Q2 2019 (Japan)
  • Pivotal P3 data in 1H 2020 (US)

Title

44%
BBI-3000
Oral rexinoid for cutaneous T-cell lymphoma
  • Completion of POC study in 2020

Title

22%
BBI-6000
Topical RORy inhibitor for psoriasis
  • Completion of POC study in 2021

Title

7%
BBI-5000
Oral CRTH2 antagonist for androgenic alopecia
  • Completion of Phase 2b study in 2021

Title

22%
BBI-2000
Topical anti-inflammatory peptide for allergic contact dermatitis
  • Completion of 2nd POC study in 2021

Title

28%
HELPFUL RESOURCES FOR PATIENTS